Akebia Therapeutics, Inc. (AKBA)
收市後：
| 前收市價 | 1.3700 |
| 開市 | 1.3400 |
| 買盤 | 1.3200 x 2800 |
| 賣出價 | 1.3500 x 2800 |
| 今日波幅 | 1.3100 - 1.3500 |
| 52 週波幅 | 0.7800 - 2.4800 |
| 成交量 | |
| 平均成交量 | 4,867,730 |
| 市值 | 286.84M |
| Beta 值 (5 年，每月) | 0.84 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.2700 |
| 業績公佈日 | 2024年5月06日 - 2024年5月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 5.00 |
BenzingaFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e
ZacksAkebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Barrons.comAkebia Awaits FDA Word On Second Crack At Vadadustat
The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included safety data from tens of thousands of patients in Japan, where vadadustat was approved in mid-2020. Akebia has said it is prepping for a U.S. commercial launch of vadadustat in the second half if it gets an FDA green light.
